Viage Therapeutics was established by Remiges Ventures, based on the ground-breaking research of Dr. Kousaku Ohinata from Kyoto University. Food affects mood, so Dr. Ohinata was inspired to identify active pharmaceutical ingredients that had origins in proteins from food sources. His well-published research describes numerous peptides that act in the gastrointestinal tract and stimulate the central nervous system via the vagus nerve. VNS (vagus nerve stimulation) is a well-established mode of action, with FDA approved devices for resistant epilepsy and refractory depression. Viage’s pipeline includes SAR-optimized drug candidates with potential in depression, anxiety, inflammatory disease, tinnitus, and others. The drug candidates are gut-acting and gut-restricted, which suggests an advantageous safety profile, particularly compared to most approved psychiatric drugs which suffer from numerous side effects.